All News

17 November 2010

Morphotek, Inc. Announces Initiation of a Sponsored Research Agreement (SRA) with Hokkaido University to Evaluate Amatuximab (MORAb-009) in Advanced Pancreatic CancerAntibodies

17 November 2010

HUMAN GENOME SCIENCES AND GLAXOSMITHKLINE ANNOUNCE VOTE OF FDA ADVISORY COMMITTEE TO RECOMMEND APPROVAL OF BENLYSTA FOR SYSTEMIC LUPUS ERYTHEMATOSUSAntibodies

17 November 2010

Peregrine’s Bavituximab Demonstrates Broad Potential in Viral Hemorrhagic Fever Infection ModelsAntibodies

16 November 2010

Anthera Pharmaceuticals, Inc. (ANTH) Suspends Enrollment and Dosing in PEARL-SC Clinical Trial to Address Reports of Vial ProblemsAntibodies

16 November 2010

ALLOZYNE Announces Positive Proof of Concept Data for AZ17, a Bispecific Th17 Antagonist for Treatment of Autoimmune DiseasesAntibodies

15 November 2010

BioWa Announces License of POTELLIGENT Technology to AgensysAntibodies

11 November 2010

Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI® Label to Include Inhibition of Structural Damage in Treatment of Psoriatic ArthritisAntibodies

10 November 2010

BioInvent Announces Approval to Start Phase II Trial for Its Novel Cardiovascular Drug BI-204Antibodies

10 November 2010

Positive XOMA 052 Results in Inflammatory Eye Disease – Behcet’s Uveitis – Presented at American College of Rheumatology Scientific MeetingAntibodies

9 November 2010

Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus ErythematosusAntibodies

9 November 2010

ABLYNX ELIGIBLE FOR MILESTONE PAYMENT AS PFIZER INITIATES PHASE I CLINICAL TRIAL WITH A SECOND ANTI-TNF-alpha NANOBODYAntibodies

9 November 2010

Published Results Show Denosumab Superior to Zometa(R) in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast CancerAntibodies

8 November 2010

New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE After Inadequate Response to Enbrel or Humira Demonstrate Marked Clinical ImprovementAntibodies

8 November 2010

New Data Show That Subcutaneous Injection of an Investigational Formulation of ORENCIA (abatacept) Provided Similar Improvements in Disease Activity Compared to Intravenous Administration of ORENCIAAntibodies

8 November 2010

Micromet to Advance BiTE Antibody MT112/BAY 2010112 into IND-Enabling Preclinical Development Activities in Collaboration with Bayer Schering PharmaAntibodies

5 November 2010

Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR MeetingAntibodies

3 November 2010

Bristol-Myers Squibb Announces that the U.S. Food and Drug Administration Has Extended the Review Timeline for the Ipilimumab Biologics License ApplicationAntibodies

1 November 2010

MabThera approved in Europe for first line maintenance treatment of follicular lymphoma, a common type of blood cancerAntibodies

29 October 2010

Compugen Licenses Novel Oncology Target to Seattle GeneticsAntibodies

27 October 2010

Laureate Pharma Announces New Development and Manufacturing Agreement to Produce AVEO Pharmaceuticals’ Antibody TherapeuticAntibodies

26 October 2010

Genmab Announces Start of Ofatumumab Phase III Head to Head Study in Follicular LymphomaAntibodies

26 October 2010

Ablexis Cuts Deal With Pfizer Inc. (PFE), Four Other Pharmas, For Antibody Drug Discovery Tool in Deal Worth up to $50 MillionAntibodies

26 October 2010

Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART-Based Antibody TherapeuticsAntibodies

21 October 2010

Alexion Announces Interim Results from Phase 2 Trials of Eculizumab (Soliris) in Patients with atypical Hemolytic Uremic Syndrome (aHUS)Antibodies

21 October 2010

FDA Approves Herceptin For HER2-Positive Metastatic Stomach CancerAntibodies

21 October 2010

MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy EndpointAntibodies

20 October 2010

Agensys, an Affiliate of Astellas, and Seattle Genetics Announce Initiation of Phase I Clinical Trial of ASG-5ME for Prostate CancerAntibodies

19 October 2010

MorphoSys Opts for Second Pre-Development Program within Strategic Antibody AllianceAntibodies

18 October 2010

UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn’s DiseaseAntibodies

18 October 2010

Phase II study with ocrelizumab shows significant reduction in disease activity for multiple sclerosis patientsAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Nectin-4-Targeted Immunotherapy Pipeline Review

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

CCR8-Targeted Antibody Immunotherapy Pipeline Review

B7-H4 Targeted Antibody Therapy Pipeline Review

CD73 Inhibitor Pipeline Review